Sipoglitazar is primarily used in the management of type 2 diabetes mellitus. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPARs), specifically targeting PPAR-alpha and PPAR-gamma receptors. By activating these receptors, it helps improve insulin sensitivity, reduce blood glucose levels, and regulate lipid metabolism. This makes it effective in controlling hyperglycemia and addressing dyslipidemia, which are common complications in diabetic patients. Additionally, it may contribute to reducing the risk of cardiovascular complications associated with diabetes. Its dual-action mechanism offers a comprehensive approach to managing metabolic disorders in patients with type 2 diabetes.